What we do Jenburkt Pharmaceuticals Ltd manufactures and markets specialty pharmaceutical formulations and healthcare products in India and 13 countries. It focuses on quality healthcare and innovation in pain management and wellness. |
Founded in 1,985 |
Market share Strong presence in India with over 1,000 stockists and reach to 400,000+ pharmacies globally; expanding in wellness segment. |
Problem solved Provides affordable, high-quality medicines and wellness products addressing pain management, chronic diseases, and holistic health needs. |
Top clients or who we serve Government bodies, semi-government institutions, missionary hospitals, public sector enterprises, and retail pharmacies; B2B and B2C focus. |
Key management Shri Ashish U. Bhuta, Chairman and Managing Director; Shri Dilip H. Bhuta, Whole Time Director & CFO; appointed directors possess strong governance credentials. |
Our journey and innovations Founded as a joint venture in 1985, expanded internationally, strengthened manufacturing per WHO GMP, launched OTC wellness division and digitally transformed marketing. |
Where we operate India and exports to 13 countries including Sri Lanka; growing footprint in key Indian states across wellness and pharma divisions. |
Top products or what we offer Pharmaceutical formulations in primary care, pain management products like Powergesic 4X and Zixflam Forte, and wellness brands including Zixa Strong and Nervijen D3. |
Top brands Zixa Strong (natural pain relief), Nervijen D3 (high revenue brand), Powergesic 4X spray, Zixflam Forte, Ortho Pain Massage Oil, Multi-Action Balm. |
Raw materials needed Active Pharmaceutical Ingredients (APIs) and other pharma-grade raw materials compliant with regulatory standards. |
Raw materials supplier Sources likely include domestic and international API suppliers aligning with quality and regulatory norms. |
Recurring vs cyclical contribution Revenue predominantly recurring from pharmaceutical formulations and wellness product sales, with steady export contributions. |
Our industry position Respected mid-sized pharma with 8% revenue growth, strong profit margins, and a growing wellness segment; recognized for compliance and quality. |
Financial highlights FY2025 revenue at ₹151.69 crore, profit after tax ₹32.06 crore; 8% YoY revenue growth; profit up 23%, EPS increased to ₹72.65. |
Geographical revenue split Approx. 87% domestic (Local) and 13% export revenue as of FY2025. |
Order book - |
Whats driving growth Product innovation, digital marketing transformation, new product launches, expanding wellness division, and increasing doctor engagement programs. |
Our future plans Expand wellness footprint nationally, continue R&D in pain management and chronic care, implement digital tools, and deepen international market penetration. |
Our green promise No specific details disclosed; committed to ethical business and compliance with regulatory practices. |
Our people and values 54% women in plant workforce; strong culture of teamwork, performance, agility, and leadership development. |
Key challenges ahead Regulatory compliance, pricing controls, dependence on China for APIs, navigating market fluctuations, and maintaining innovation pace. |
Interesting facts World Health Organization-approved manufacturing; launched India's first OTC Nervijen D3 with outstanding revenue; digital e-detailing revamped marketing. |
Risks and strategy Mitigates regulatory and supply chain risks by investing in compliance, innovation, local API sourcing, and robust governance. |
